UPDATE: BMO Capital Markets Raises PT on Merck & Co. on 1Q13 Preview, Long-Term Outlook
April 19, 2013 at 10:59 AM EDT
In a report published Friday, BMO Capital Markets analyst Alex Arfaei reiterated an Outperform rating on Merck & Co. (NYSE: MRK ), and raised the price target from $47.00 to $51.00. In the report, Arfaei noted, “We are providing our 1Q13 preview and longer term outlook for Merck. Although Merck
